Stock listing

Zai Lab Ltd.

Selected listing: A2DX1V · LS · EUR · DE

Zai Lab Ltd. (Lang & Schwarz: A2DX1V), Health Technology. Latest release Jul 22, 2026: Zai Lab to Announce Second Quarter 2026 Financial Results and Recent…

A2DX1V:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2DX1V
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Zai Lab Ltd.

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

June 8, 2026

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

May 11, 2026

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

May 7, 2026

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

April 22, 2026

All Zai Lab Ltd. news →

Events

Replays

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call
Thu, Aug 06, 2026 · 08:00 AM ET
Watch
Zai Lab Limited (ZLAB) Q1 2026 Earnings Call
Thu, May 07, 2026 · 08:00 AM ET
Watch
Zai Lab Limited (ZLAB) Q4 2025 Earnings Call
Thu, Feb 26, 2026 · 08:00 AM ET
Watch

Research Zai Lab Ltd.

Zai Lab Ltd. company profile

View the public company page for Zai Lab Ltd. on 6ix.

Zai Lab Ltd. news

Read company news and market updates connected to Zai Lab Ltd..

Zai Lab Ltd. investor events

Find investor webinars, events, and replay context for Zai Lab Ltd..